How CROs Are Succeeding With A Holistic Patient Convenience Strategy

By Dave Espenshade, VP, CRO Partnerships

In the current landscape, patient and site convenience has transitioned from being a luxury to a pivotal element of successful clinical trial operations. As the life science industry confronts a growingly intricate scenario, marked by evolving patient expectations, higher trial volumes, and the emergence of decentralized dynamics, it faces operational hurdles for sponsors who aim to expedite drug development for maximal revenue and effective patient treatment.

For CROs, these hurdles are embraced as opportunities.

Over time, CROs have become integral to drug development. They comprehend the objectives of their pharmaceutical counterparts and serve as innovation collaborators, piecing together optimal solutions to achieve overarching study objectives. Dive into this article, where author Dave Espenshade sheds light on how CROs can improve access, increase engagement, and drive outcomes through better patient experiences.